Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) EBITDA (2018 - 2025)

Historic EBITDA for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$4.6 million.

  • Serina Therapeutics' EBITDA fell 42617.02% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.6 million, marking a year-over-year decrease of 37555.11%. This contributed to the annual value of -$17.0 million for FY2024, which is 44483.86% down from last year.
  • As of Q3 2025, Serina Therapeutics' EBITDA stood at -$4.6 million, which was down 42617.02% from -$5.6 million recorded in Q2 2025.
  • Serina Therapeutics' 5-year EBITDA high stood at $1.4 million for Q3 2024, and its period low was -$5.9 million during Q1 2025.
  • Moreover, its 5-year median value for EBITDA was -$1.9 million (2021), whereas its average is -$2.3 million.
  • Within the past 5 years, the most significant YoY rise in Serina Therapeutics' EBITDA was 19637.73% (2024), while the steepest drop was 240248.96% (2024).
  • Over the past 5 years, Serina Therapeutics' EBITDA (Quarter) stood at -$1.9 million in 2021, then rose by 4.55% to -$1.8 million in 2022, then surged by 113.52% to $241000.0 in 2023, then plummeted by 2402.49% to -$5.5 million in 2024, then rose by 17.12% to -$4.6 million in 2025.
  • Its last three reported values are -$4.6 million in Q3 2025, -$5.6 million for Q2 2025, and -$5.9 million during Q1 2025.